<- Back to digest

JOA - 2026-11-05 - Journal Article

Cefazolin Administration in Patients Who Have Severe Penicillin Allergy Undergoing Total Joint Arthroplasty: A Prospective Observational Study.

Samineni AV, Cruz-Ossa N, Reddy GB, McNamara CA, Hernandez VH, D'Apuzzo MR

prospective cohortLOE IIn = 516 hours postoperatively for primary endpoint; SSI/PJI follow-up duration not reported.

Topics

arthroplasty
PMID: 42988282DOI: 10.1016/j.arth.2026.10.052View on PubMed ->

Key Takeaway

Zero allergic reactions occurred in 51 patients with documented severe penicillin allergy who received cefazolin for THA or TKA (0/51; 95% CI 0–7.0%).

Summary Depth

Choose how much analysis to show on this article page.

Summary

This prospective observational study evaluated cefazolin safety in 51 THA/TKA patients with documented severe penicillin allergy (SPA) at a single institution between July 2024 and October 2025. All patients received standard cefazolin prophylaxis; the primary endpoint was intraoperative or 6-hour postoperative allergic reaction. Zero reactions occurred (0/51; 95% CI 0–7.0%), and no SSI or PJI events were reported.

Key Limitation

The sample size yields a 95% CI upper bound of 7.0%, meaning a clinically meaningful reaction rate cannot be excluded, and the study is underpowered to detect rare but serious events such as anaphylaxis.

Original Abstract

BACKGROUND

Cefazolin is the recommended perioperative antibiotic for total hip (THA) and knee arthroplasty (TKA) due to its bone penetration and broad-spectrum efficacy. However, patients labeled with severe penicillin allergy (SPA) are often denied cefazolin due to concerns about cross-reactivity, despite limited evidence supporting this practice. This prospective observational study evaluated the safety of cefazolin in this population.

METHODS

Between July 2024 and October 2025, 1,234 elective THA and TKA procedures were performed at our institution. Our prospective observational study enrolled 51 patients (4.1%) who had a documented severe penicillin allergy (mean age 67 years; 70.6% women; and 76.5% Hispanic). Patients completed a preoperative questionnaire detailing allergy duration, exposure source, and reaction types. Standard perioperative protocols, including cefazolin administration and timing, were utilized. The primary endpoint was the development of allergic reactions (e.g., anaphylaxis, rash), either intraoperatively or six hours postoperatively. The secondary endpoints included surgical site infection (SSI) and periprosthetic joint infection (PJI). Descriptive statistics were used for the analysis.

RESULTS

Of the 51 SPA patients, seven (13.7%) had documented penicillin allergies that were also confirmed by skin testing. Questionnaire results showed allergies lasted a mean of 42.9 years. Reaction types included severe skin rash (58.8%), dyspnea (56.9%), body swelling (45.1%), face swelling (35.3%), severe pruritus (45.1%), wheezing (35.3%), and anaphylaxis (15.7%). Most patients (86.3%) reported two to five of these reactions. There were no intraoperative or immediate postoperative allergic reactions that occurred with cefazolin use (zero of 51; 95% confidence interval 0 to 7.0).

CONCLUSION

There were no perioperative allergic reactions observed among 51 patients who had reported severe penicillin allergy and received cefazolin. These findings represent a preliminary prospective safety signal and require confirmation in larger studies.